Dopamine modulation clinical effects

Safinamide is in Phase 111 clinical trials for Parkinson disease. The molecule possesses multiple mechanisms of action it combines inhibition of dopamine uptake and potent, selective, and reversible inhibition of MAO-B, sodium (Na" ") channel blockage, and calcium channel modulation, while being devoid of a MAO-A inhibitory effect (Figure 8.37). 

Positive inotropic compounds can be classified into three groups cAMP generators, intracellular calcium regulators, and modulators of ion channels or pumps [11]. The cAMP generators such as dopamine, dobutamine, and milrinone (a phosphodiesterase inhibitor) may worsen ischemia, cause arrhythmias, and increase mortality [2,6]. Intracellular calcium modulators have not reached clinical use, possibly because of additional effects such as vasoconstriction,... 

---